ClinicalTrials.Veeva

Menu

Pediatric NMOSD Observational Study

Mayo Clinic logo

Mayo Clinic

Status

Completed

Conditions

Neuromyelitis Optica
NMO Spectrum Disorder

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT03766347
17-005618

Details and patient eligibility

About

This study is being done to develop a database of pediatric patients in order to study the cause, early detection and best treatment for neuromyelitis optica spectrum disorder (NMOSD) in pediatric patients.

Full description

This study is being done to collect information on the natural history of NMOSD in pediatric AQP4-IgG seropositive patients. A major restriction in performing drug studies in pediatric patients with NMOSD is limited information on the course of the disease in these patients. Collecting clinical information over the course of a 1 year observational study would inform on the natural history of the disease in these patients. A repository of pediatric patients with rare diseases can increase knowledge on the natural history of the specific disease, assist in identifying appropriate patients fulfilling specified criteria for drug studies and potentially serve as a control group.

Timepoints: Baseline, 3mo, 6mo, 9mo, 12mo (+/- 1 mo for each time point).

Baseline data:

  • Demographics [age/sex/ethnicity],
  • Clinical presentation information including date of initial diagnosis,
  • Clinical phenotype
  • Immunotherapy used current and past,
  • Family history of autoimmune diseases,
  • Serological data results
  • Radiologic data as available

Self-Report Assessments will be:

  • Current impairment, as measured by the expanded disability status scale (EDSS) score self-reported using Ratzker (1997) EDSS Self Report form,
  • Quality of life as measured by the EQ-5D and Varni's (1998) PedsQL over the phone/mail/email.

At follow-up visits 3mo, 6mo, 9mo, 12mo (+/- 1 mo for each time point):

  • Attacks/relapses
  • Any hospitalizations
  • Confirm medications and update records if changes

Self-Report Assessments at follow-up will be:

  • Current impairment, as measured by the EDSS score self-reported using Ratzker (1997) EDSS Self Report form,
  • Quality of life as measured by the EQ-5D and PedsQL over the phone/mail/email.

Enrollment

100 patients

Sex

All

Ages

2 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • AQP4 positive
  • Ability to give informed consent by patient or caregiver

Exclusion criteria

  • Inability to complete required forms via phone, mail, or email.

Trial design

100 participants in 1 patient group

Pediatric Neuromyelitis Optica
Description:
Participants under the age of 18 that are positive for Aquaporin-4 antibody.

Trial contacts and locations

1

Loading...

Central trial contact

Melissa L Bush

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems